[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623211":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Exposure Group: XFJZD + Western Medicine",null,"Patients diagnosed with influenza-induced AECOPD who choose to receive Xuanfei Jiangzhuo Decoction (XFJZD) combined with standard Western medicine based on personal preference and physician recommendations. XFJZD is administered orally as a liquid decoction, 200 mL per dose, twice daily for 5 days. They also receive standard antiviral therapy (Oseltamivir or Baloxavir marboxil) and routine COPD maintenance therapy.",[13,14],"Drug: Xuanfei Jiangzhuo Decoction","Drug: Standard Antiviral Therapy (Oseltamivir or Baloxavir marboxil)",{"label":16,"type":10,"description":17,"interventionNames":18},"Non-Exposure Group: Standard Western Medicine","Patients diagnosed with influenza-induced AECOPD who choose to receive standard Western medicine alone based on personal preference. This includes standard antiviral therapy (Oseltamivir or Baloxavir marboxil) and routine maintenance therapy for COPD (e.g., ICS\u002FLABA\u002FLAMA, theophylline, roflumilast). This group does not receive the XFJZD intervention.",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Xuanfei Jiangzhuo Decoction","A traditional Chinese medicine composite formula derived from Maxing Shigan Tang and Shengjiang San. It is administered orally as a liquid decoction, 200 mL per dose, twice daily (morning and evening, 30 minutes after meals) for 5 days.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Standard Antiviral Therapy (Oseltamivir or Baloxavir marboxil)","Patients receive standard antiviral treatment according to clinical guidelines and physician judgment. Medications include Oseltamivir (e.g., 75 mg twice daily for 5 days) or Baloxavir marboxil (singl",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Caiyan Jia","CONTACT","15532388243","jcy19990506@163.com",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality","300052","China","CN",{"type":44,"coordinates":45},"Point",[46,47],117.17667,39.14222,{"lat":47,"lon":46},[50,54],{"name":51,"role":32,"phone":52,"phoneExt":10,"email":53},"Baoshan Liu, PhD","+86 15532388243","jiacy0605@tmu.edu.cn",{"name":31,"role":32,"phone":10,"phoneExt":10,"email":34},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yanqi Song","Attending Physician","100623211","effectiveness-of-xuanfei-jiangzhuo-decoction-for-influenza-induced-aecopd-100623211",false,"NCT07393685","Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","Effect of Xuanfei Jiangzhuo Decoction on Clinical Remission in Influenza-Induced AECOPD: Study Protocol for a Prospective, Real-World Cohort Study","Inclusion Criteria:\n\n* Diagnosed with Influenza-induced AECOPD according to the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2025) and the Expert Consensus on the Diagnosis and Treatment of AECOPD in China (Updated 2023), confirmed by spirometry and viral testing (antigen or PCR), and excluding pneumonia and heart failure via chest CT and NT-proBNP.\n* Aged 60 years or older.\n* Voluntarily participate and provide written informed consent..\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any component of the study medications.\n* Presence of severe bacterial co-infection at enrollment requiring systemic antibiotic therapy.\n* Severe dysfunction of major organs that may interfere with efficacy or safety assessment (e.g., severe cardiac insufficiency, hepatic impairment, or renal failure).\n* Participation in other interventional clinical trials within the past 3 months.\n* Inability to be contacted for follow-up (e.g., lack of permanent address or valid contact information).\n* Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation (e.g., severe cognitive impairment or psychiatric disorders).","ALL","60 Years",{"count":69,"type":70},300,"ESTIMATED","28 Days","OBSERVATIONAL","The goal of this observational study is to learn if a traditional Chinese herbal medicine (Xuanfei Jiangzhuo Decoction) works to help older adults recover from a COPD flare-up caused by the flu (influenza virus). The main questions it aims to answer are:\n\nDoes the herbal medicine help participants feel better and recover faster? Does it lower the chance of getting a second infection from bacteria? Is the herbal medicine safe to use? Researchers will compare participants who choose to take the herbal medicine along with their standard flu treatment (Oseltamivir or Baloxavir) to participants who only take the standard flu treatment (Oseltamivir or Baloxavir).\n\nParticipants will:\n\nTake the herbal medicine (a liquid drink) twice a day for 5 days, or just take their standard flu medicine for 5 days.\n\nVisit the clinic 4 times over 28 days for checkups and tests. Provide blood and stool samples to help researchers understand how the medicine affects the body and gut health.\n\nAnswer simple questions about their cough, breathing, and energy levels.",[75,76,77],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Influenza, Human","Virus Diseases",[79,80,81],"COPD Exacerbation","Real-World Study","Traditional Chinese Medicine","NOT_YET_RECRUITING","2026-03-09",{"date":85,"type":86},"2026-03-12","ACTUAL",{"date":88,"type":70},"2026-08-01",{"date":90,"type":70},"2028-05-31",{"name":5,"class":6},1]